Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0292 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Joao Paulo Solar Vasconcelos und 13 weiteren Autor:innen. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) constitute a heterogeneous group of incurable cancers. Lenvatinib is an oral multiple kinase inhibitor that showed activity in grade 1/2 GEP-NENs in the phase II TALENT trial, but a confirmatory phase III study has yet to be conducted. To investigate the real-world use of lenvatinib in treating patients with advanced GEP-NENs, we retrospectively analyzed a cohort of adults with unresectable neuroendocrine neoplasms (NENs) from two academic centers in Canada who received palliative treatment with lenvatinib. Progression-free survival (PFS), overall survival (OS) and the treating clinician assessment of best therapeutic response were analyzed in the entire cohort and in the subgroup of patients with GEP-NENs that would have been eligible for the TALENT trial. Overall, 33 patients, with mostly G1/G2 (78.8%) metastatic NENs, received lenvatinib. The pancreas was the most common primary site (n = 16, 48.5%), followed by the small bowel (n = 12, 36.4%). The median number of prior lines of systemic therapy was 2 (range 1–5). The median initial, maximal and minimal doses (mg) were 12 (range 4–24), 12 (range 8–24) and 8 (range 4–24), respectively. The median PFS was 11.9 months (95% CI, 9.5–NA), and the median OS was 17.5 months (95% CI, 12.7–NA), with disease burden reduction seen in 21.9% (95% CI, 11.0–38.7) and 87.5% (95% CI, 71.9–95.3) of patients achieving disease control. The most frequent side effects reported were hypertension (60.6%), fatigue (39.4%), hypothyroidism (21.2%) and diarrhea (18.2%). This real-world cohort demonstrates encouraging evidence of lenvatinib activity in metastatic NENs, even when used at lower doses than previously studied in NENs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Joao Paulo Solar Vasconcelos, Ali Zaidi, Jonathan M Loree
Zitieren
APA
Solar Vasconcelos, J. P., Nunez Rodriguez, J. E., Zaidi, A., Krishnan, T., Jafari, H., Gill, S., Tan, A., Le, D., Chan, T., Yu, S., McGhie, J. P., Lim, H., Singh, S., & Loree, J. M. (2025). Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0292
Vancouver
Solar Vasconcelos JP, Nunez Rodriguez JE, Zaidi A, Krishnan T, Jafari H, Gill S, et al. Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0292
BibTeX
@article{SolarVasconcelos2025,
author = {Solar Vasconcelos, Joao Paulo and Nunez Rodriguez, Jose Eduardo and Zaidi, Ali and Krishnan, Tharani and Jafari, Helia and Gill, Sharlene and Tan, Ann and Le, Dan and Chan, Theresa and Yu, Simon and McGhie, John Paul and Lim, Howard and Singh, Simron and Loree, Jonathan M},
title = {Real-world outcomes of lenvatinib therapy for advanced neuroendocrine neoplasms},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0292}
}
EUVIMED